New ant i retro viral agents for the therapy of HIV type-1 infection

    loading  Checking for direct PDF access through Ovid


A variety of antiretroviral agents are currently under clinical evaluation as anti-HIV-1 therapies. Categorically, these agents differ in the mechanisms by which they inhibit HIV-1 replication and include new, second generation, nucleoside analog reverse transcriptase inhibitors (stavudine, 3TC and FTC), non-nucleoside reverse transcriptase inhibitors (nevirapine, L-697,661 and atevirdine), interferon-cc, viral protease inhibitors (Ro 31-8959 and A77003), and an inhibitor of HIV-1 tat (Ro 5-3335). All of these drugs effectively inhibit HIV-1 replication in cell culture and have shown promise in the inhibition of HIV-1 replication in vivo, either alone or in combination with other antiretroviral agents. Although these agents are currently not approved for general use, it is likely that several will be available as anti-HIV-1 therapies in the near future, pending the outcome of ongoing trials.

Related Topics

    loading  Loading Related Articles